April 24 (Reuters) - German biotech company CureVac sued Moderna (MRNA.O), opens new tab in Delaware federal court on Friday, alleging that Moderna's COVID-19 vaccine Spikevax infringed CureVac ...

Moderna’s first big success was its coronavirus vaccine -- that product brought in $18 billion in revenue at its peak. The biotech recently submitted a flu vaccine candidate to regulators. But Moderna ...

Moderna CEO Stéphane Bancel’s total compensation remained remarkably stable last year at $19.9 million, even as the vaccines company navigated a “challenging regulatory and business environment.” ...

A member of the Riverside Poly High cross country team booster club has been charged with embezzlement after Riverside police say she stole $12,000. Catherine Beckman, 48, was scheduled to enter a ...

Moderna, Inc. settles its LNP patent dispute with Arbutus and Genevant for a $950 million upfront payment, eliminating a major litigation overhang. MRNA secures royalty-free access to critical LNP ...

Moderna MRNA.O has agreed to pay Genevant Sciences, a subsidiary of Roivant Sciences ROIV.O, and Arbutus Biopharma ABUS.O up to $2.25 billion to settle a long-running legal fight over the technology ...

Moderna MRNA0.74%increase; green up pointing triangle will pay $950 million to settle patent litigation by Arbutus Biopharma and Genevant Sciences GmbH. The vaccine maker said Tuesday that, as part of ...

Jason is a general assignment reporter, with particular focus on genetic medicine and rare disease. Confidential tips can be sent on Signal at JasonMast.77. This story has been updated. Moderna has ...

Moderna seeks to return to growth Its share price has lost 90% from pandemic peaks Anti-vaccine health secretary has disrupted US vaccine policy Feb 27 (Reuters) - Europe's medicines regulator ...